| Income statement (USD) | Q4 2026 ended Jun 30, 2026 | Q3 2026 ended Mar 31, 2026 | Q2 2026 ended Dec 31, 2025 | Q1 2026 ended Sep 30, 2025 | Q4 2025 ended Jun 30, 2025 | Q3 2025 ended Mar 31, 2025 | Q2 2025 ended Dec 31, 2024 | Q1 2025 ended Sep 30, 2024 |
|---|---|---|---|---|---|---|---|---|
| Research and development | 375.7K | 169.7K | 20.0K | 60.2K | 53.5K | 54.1K | 54.4K | 61.7K |
| Operating expenses | 3.46M | 6.40M | 3.65M | 4.67M | 3.65M | 53.13M | 213.4K | 290.8K |
| Operating income | -3.46M | -6.40M | -3.65M | -4.67M | -3.65M | -53.13M | -213.4K | -290.8K |
| EBITDA | -3.46M | -6.40M | -3.65M | -4.67M | -53.13M | |||
| Interest expense | 27.7K | 38.3K | 59.0K | 305.6K | 254.5K | 104.0K | 118.9K | 86.2K |
| Income before tax | -4.57M | -6.36M | -3.09M | -4.84M | -4.07M | -54.07M | -430.2K | -354.3K |
| Net income | -4.57M | -6.36M | -3.09M | -4.84M | -4.07M | -54.07M | -430.2K | -354.3K |
| EPS | 6.20 | -7.09 | -0.30 | -0.39 | 594.27 | -312.46 | -32.23 | -35.97 |
| EPS (diluted) | 6.20 | -7.09 | -0.30 | -0.39 | 594.27 | -312.46 | -32.23 | -35.97 |
| Diluted shares | 484.8K | 897.1K | 13.36M | 12.33M | 101.9K | 173.0K | 13.3K | 9.8K |
From Propanc Biopharma, Inc.'s 10-K and 10-Q filings with the SEC. Fourth quarters, and quarters where the company only reported year-to-date totals, are worked out by subtracting the earlier quarters. Fiscal years are the company's own, so they may not match the calendar. A blank cell means the company did not report that line. New to this? Read income statement or reading a 10-K.
Revenue, earnings, margins and balance sheet trends drawn by TradingView from its own data, so figures can differ slightly from the SEC table above.